Bli medlem
Bli medlem

Du är här


Galapagos NV: Transparency notification - Gilead Sciences, Inc. holds 14.75% of Galapagos shares

Mechelen, Belgium; 25 January 2016 - Transparency notification to Galapagos NV
(Euronext&NASDAQ: GLPG) -
Gilead Sciences, Inc. (NASDAQ: GILD) crosses a 10% threshold of Galapagos'
voting rights, to a 14.75% shareholding in Galapagos.

Pursuant to Belgian transparency legislation[1], Galapagos NV ("Galapagos")
and Gilead Sciences, Inc. ("Gilead") have filed a joint transparency
notification on 22 January 2016. The transparency notification announces
that Gilead, as a result of its entirely-controlled subsidiary Gilead
Biopharmaceutics Ireland Unlimited Company subscribing to a capital increase
and thus receiving 6,760,701 new Galapagos shares on 19 January 2016,
indirectly holds 14.75% of the current 45,837,043 outstanding Galapagos
shares. Gilead therefore crossed a 10% threshold of Galapagos' voting rights
on 19 January 2016. Furthermore, Galapagos and Gilead are acting in concert
as a result of standstill and lock-up provisions with respect to Galapagos
shares held by Gilead contained in their global collaboration agreement for
the development and commercialization of the JAK1-selective inhibitor
filgotinib. The full transparency notice is available for viewing on the
Galapagos website.

About Galapagos

Galapagos(Euronext&NASDAQ: GLPG) is a clinical-stage biotechnology company
specialized in the discovery and development of small molecule medicines with
novel modes of action. Our pipeline comprises three Phase 2, four Phase 1,
five pre-clinical, and 20 discovery studies in cystic fibrosis, inflammation,
fibrosis, osteoarthritis and other indications. We have discovered and
developed filgotinib: in collaboration with Gilead we aim to bring this
JAK1-selective inhibitor for inflammatory indications to patients all over
the world. Galapagos is focused on the development and commercialization of
novel medicines that will improve people's lives. The Galapagos group,
including fee-for-service subsidiaryFidelta, has approximately 400 employees,
operating from its Mechelen, Belgium headquarters and facilities in The
Netherlands, France, and Croatia. More information

Galapagos Contacts

Investors: Media:

Elizabeth Goodwin Evelyn Fox
VP IR&Corporate Communications Director Communications
+1 781 460 1784 +31 6 53 591 999

Galapagos Forward-Looking Statements

This release may contain forward-looking statements. Galapagos cautions the
reader that forward-looking statements are not guarantees of future
performance. Forward-looking statements involve known and unknown risks,
uncertainties and other factors which might cause the actual results,
financial condition and liquidity, performance or achievements of Galapagos,
or industry results, to be materially different from any historic or future
results, financial conditions and liquidity, performance or achievements
expressed or implied by such forward-looking statements. In addition, even
if Galapagos' results, performance, financial condition and liquidity, and
the development of the industry in which it operates are consistent with such
forward-looking statements, they may not be predictive of results or
developments in future periods. Among the factors that may result in
differences are the inherent uncertainties associated with competitive
developments, clinical trial and product development activities and
regulatory approval requirements, Galapagos' reliance on collaborations with
third parties, and estimating the commercial potential of our product
candidates. A further list and description of these risks, uncertainties and
other risks can be found in the company's Securities and Exchange Commission
filing and reports, including in the company's prospectus filed with the
Securities and Exchange Commission on May 14, 2015 and subsequent filings and
reports filed by the company with the Securities and Exchange Commission.
Given these uncertainties, the reader is advised not to place any undue
reliance on such forward-looking statements. These forward-looking
statements speak only as of the date of publication of this document.
Galapagos expressly disclaims any obligation to update any such
forward-looking statements in this document to reflect any change in its
expectations with regard thereto or any change in events, conditions or
circumstances on which any such statement is based or that may affect the
likelihood that actual results will differ from those set forth in the
forward-looking statements, unless specifically required by law or
---------------------------------------[1] Belgian Act of 2 May 2007 on the disclosure of major shareholdings in
issuers whose shares are admitted to trading on a regulated market

Transparancy notification - Gilead holds 14,75% Galapagos shares


This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Galapagos NV via Globenewswire


Författare Hugin

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.